Trial Profile
A Multicenter, International, Prospective, Randomized, Vehicle Controlled, Assessor Blinded Study Performed in Subjects With Hard to Heal Wounds, to Evaluate the Efficacy and Safety of Enzymatic Debridement With EscharEx
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs EscharEx (Primary)
- Indications Leg ulcer; Wounds
- Focus Therapeutic Use
- Sponsors MediWound
- 09 Jul 2021 Results presented in a MediWound media release.
- 09 Jul 2021 According to a MediWound media release, results from this study have been published in the Wound Repair and Regeneration Journal.
- 29 Aug 2018 Status changed from recruiting to completed.